<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03208179</url>
  </required_header>
  <id_info>
    <org_study_id>16.049</org_study_id>
    <nct_id>NCT03208179</nct_id>
  </id_info>
  <brief_title>Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa</brief_title>
  <acronym>IMPROVE</acronym>
  <official_title>IPTp With Dihydroartemisinin-piperaquine and Azithromycin for Malaria, Sexually Transmitted and Reproductive Tract Infections in Pregnancy in High Sulphadoxine-pyrimethamine Resistance Areas in Kenya, Malawi and Tanzania: an International Multi-centre 3-arm Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liverpool School of Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>College of Medicine, University of Malawi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malawi-Liverpool-Wellcome Trust Clinical Research Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kilimanjaro Christian Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tampere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Intellectual Ventures Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiabase, Banook Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foundation for Innovative New Diagnostics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Liverpool School of Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of monthly intermittent preventive treatment
      using dihydroartemisinin piperaquine (DP) alone or in combination with azithromycin (AZ)
      compared to sulphadoxine-pyrimthamine (SP) for the prevention of malaria in pregnant women in
      the second and third trimester.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) is one of the
      pillars of malaria prevention in pregnancy in sub-Saharan Africa, in addition to prompt case
      management and use of long lasting insecticide treated bednets. However, mounting resistance
      to SP by Plasmodium falciparum increasing renders IPTP-SP ineffective.

      Two exploratory trials in Uganda and Kenya demonstrated that IPTp with DP was superior to
      IPTp-SP for the prevention of malaria infection in pregnancy. However, neither study was
      adequately powered to look at adverse birth outcomes. This study is a confirmatory efficacy
      trial in Malawi, Tanzania and Kenya to determine the efficacy and safety of IPTp with DP
      alone or in combination with AZ.

      This will be a 3-arm trial, superiority, partial blinded, placebo controlled, randomized
      trial comparing IPTp with SP, versus IPTp with DP alone, and IPTp with DP+AZ with the
      following hypotheses:

        -  IPTp with DP is superior to IPTp with SP in preventing adverse pregnancy outcomes.

        -  The combination of DP with AZ further reduces adverse pregnancy outcomes compared to
           IPTp with DP alone.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study will be a partially placebo-controlled involving a single placebo for AZ. To further minimise bias, an objective primary outcome measure will be used and all staff will be masked to the treatment assignment of individual women. The trial statistician will also be masked in regard to the treatment code when he develops the statistical analysis plan and writes the statistical programmes, which will be validated and completed using dummy randomisation codes. The actual allocation will only be provided to the study team after locking of the database and approval of the statistical analysis plan by the independent Data Monitoring and Ethics Committee (DMEC) before they review any trial results. The study statistician conducting the interim analysis will remain masked throughout the analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse pregnancy outcome</measure>
    <time_frame>8 months</time_frame>
    <description>Composite of foetal loss (spontaneous abortion or stillbirth), or singleton live births born small-for-gestational age (SGA), or with low birthweight (LBW), or preterm (PT) (SGA-LBW-PT), or subsequent neonatal death by day 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of foetal loss and neonatal mortality</measure>
    <time_frame>8 months</time_frame>
    <description>Composite of foetal loss (spontaneous abortion or stillbirth) and neonatal mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGA-LBW-PT composite</measure>
    <time_frame>6 months</time_frame>
    <description>Composite of small for gestational age, low birth weight or preterm birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGA</measure>
    <time_frame>6 months</time_frame>
    <description>Small for gestational age using the new INTERGROWTH population reference's 10th percentile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LBW</measure>
    <time_frame>6 months</time_frame>
    <description>Low birth weight defined as a corrected birth weight below 2.5 kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PT</measure>
    <time_frame>6 months</time_frame>
    <description>Preterm birth defined as birth at a gestational age above 28 weeks but less than 37 completed weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal length and stunting</measure>
    <time_frame>8 months</time_frame>
    <description>Neonatal length and stunting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical malaria during pregnancy</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Incidence of clinical malaria during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malaria infection during pregnancy detected by microscopy and PCR</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Prevalence and incidence of peripheral maternal (blood) malaria infection during pregnancy by microscopy and PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite placental malaria detected by microscopy, by molecular methods or by histology</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Prevalence of placental malaria by microscopy, PCR and placental histology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental malaria detected by microscopy</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Prevalence of placental malaria detected in maternal placental blood by microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental malaria detected by molecular methods (PCR)</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Prevalence of placental malaria detected in maternal placental blood by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental malaria detected by histology</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Prevalence of placental malaria detected in full placental section by histology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal nutritional status</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Changes in maternal nutritional status by MUAC and BMI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal anaemia during pregnancy and delivery</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Prevalence and incidence of maternal anaemia (Hb &lt; 11g/dl) at enrolment, last antenatal visit and deivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congenital anaemia</measure>
    <time_frame>6 months from randomistion</time_frame>
    <description>Prevalence of anaemia (Hb &lt; 13g/dl) from newborn cord blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congenital malaria infection</measure>
    <time_frame>6 months from randomistion</time_frame>
    <description>Prevalence of malaria infection by microscopy or PCR from newborn cord blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc-prolongation</measure>
    <time_frame>6 months from randomistion</time_frame>
    <description>QTcF-prolongation of more than 60ms between baseline DTcF prior to first dose of DP (+/- AZ) on day 0 and repeat QTcF 4 - 6 hrs after administration of 3rd dose of DP(+/- AZ) on day 2, or QTcF &gt; 480ms, 4 - 6 hours after on day 2 treatment administration. Only on the DP containing arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congenital malformations</measure>
    <time_frame>6 months from randomistion</time_frame>
    <description>Any visible external congenital abnormality on surface examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal mortality</measure>
    <time_frame>8 months from randomisation</time_frame>
    <description>The death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management but not from accidental or incidental causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other SAEs and AEs</measure>
    <time_frame>8 months from randomisation</time_frame>
    <description>Incidence of AEs and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(History of) vomiting study drug</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Prevalence and incidence of vomiting investigational product (IP) twice at the same IP administration visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizziness</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Prevalence of dizziness after a course of IP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal complaints</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Prevalence of gastrointestinal complaints after a course of IP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular markers of drug resistance in Plasmodium falciparum infections during pregnancy and delivery</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Prevalence and incidence of SP and artemisinin resistance markers from infection isolates after enrollment and at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of STIs/RTIs prior to delivery (syphilis, gonorrhoea, Chlamydia trachomatis, Trichomonas vaginalis, and bacterial vaginosis)</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Prevalence and incidence of STIs/RTIs (syphilis, gonorrhoea, Chlamydia trachomatis, Trichomonas vaginalis, and bacterial vaginosis) at randomization and last antenatal visit prior to delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in macrolide resistance in Pneumococcus detected in maternal nasopharyngeal samples</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Prevalence and incidence of carriage of macrolide resistant pneumoccocus at randomization and delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the colony composition of maternal vaginal microbiota, and intestinal microbiota of mother and infant.</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>Changes in maternal reproductive tract and gut microbiota from randomisation to last antenatal visit prior to delivery, and neonatal gut microbiota</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">4680</enrollment>
  <condition>Pregnancy</condition>
  <condition>Malaria in Pregnancy</condition>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>IPTp-SP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stat course of 3 tablets of quality-assured SP (tablets of 500 mg of sulphadoxine and 25 mg of pyrimethamine) at each scheduled antenatal visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPTp-DP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + placebo AZ at each scheduled antenatal visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPTp-DPAZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + AZ tablet [1.5g over 3 days as 500mg per day] at each scheduled antenatal visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dihydroartemisinin-piperaquine</intervention_name>
    <description>Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin placebo</description>
    <arm_group_label>IPTp-DP</arm_group_label>
    <other_name>Eurartesim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulphadoxine-pyrimethamine</intervention_name>
    <description>Women randomised to this intervention will receive stat dose of 3 tablets of 500 mg sulphadoxine and 25 mg of pyrimethamine each (total dose of 1,500mg sulphadoxine and 75mg pyrimethamine) on a single day of clinic visit</description>
    <arm_group_label>IPTp-SP</arm_group_label>
    <other_name>Fansidar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dihydroartemisinin-piperaquine plus azithromycin</intervention_name>
    <description>Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)</description>
    <arm_group_label>IPTp-DPAZ</arm_group_label>
    <other_name>Eurartesim plus Zithromax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women between 16-28 weeks' gestation

          -  Viable singleton pregnancy

          -  Resident of the study area

          -  Willing to adhere to scheduled and unscheduled study visit procedures

          -  Willing to deliver in a study clinic or hospital

          -  Provide written informed consent

        Exclusion Criteria:

          -  Multiple pregnancies (i.e. twin/triplets)

          -  HIV-positive

          -  Known heart ailment

          -  Severe malformations or non-viable pregnancy if observed by ultrasound

          -  History of receiving IPTp-SP during this current pregnancy

          -  Unable to give consent

          -  Known allergy or contraindication to any of the study drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant female</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon K Kariuki, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenya Medical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Mosha, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kilimanjaro Christian Medical University College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Lusingu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Medical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feiko O ter Kuile, PhD</last_name>
    <phone>+447846377369</phone>
    <email>feiko.terkuile@lstmed.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mwayiwawo M Madanitsa, PhD</last_name>
    <phone>+265999616537</phone>
    <email>mwayi.madanitsa@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ahero Sud-countyHospital</name>
      <address>
        <city>Ahero</city>
        <state>Kisumu</state>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Kariuki, PhD</last_name>
      <phone>+ 254725389246</phone>
      <email>SKariuki@kemricdc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Homa Bay County Hospital</name>
      <address>
        <city>Homa Bay</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Kariuki, PhD</last_name>
      <phone>+ 254725389246</phone>
      <email>SKariuki@kemricdc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabour Sub-county Hospital</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Kariuki, PhD</last_name>
      <phone>+ 254725389246</phone>
      <email>SKariuki@kemricdc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chikwawa District Hospital</name>
      <address>
        <city>Chikwawa</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victor Mwapasa, PhD</last_name>
      <phone>+265999981496</phone>
      <email>vmwapasa@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mangochi District Hospital</name>
      <address>
        <city>Mangochi</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenneth Maleta, PhD</last_name>
      <phone>+265888232202</phone>
      <email>ken.maleta@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Handeni District Hospital</name>
      <address>
        <city>Handeni</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korogwe District Hospital</name>
      <address>
        <city>Korogwe</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Malawi</country>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2017</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Reproductive Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual, de-identified participant data will be made available for meta-analyses as soon as the data analysis is completed, with the understanding that results of the meta-analysis will not be published prior to the results of the individual trial without prior agreement of the investigators. No later than 5 years after the publication of the trial a fully de-identified data set will be available for sharing purposes</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

